Could Yescarta in 2L LBCL Receive a CHMP Positive Opinion This Week?

On Monday, May 16, the CHMP agenda for May was released. Of note, Yescarta in 2L LBCL has been listed as for adoption under ‘Type II variations – variation of therapeutic indication’.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.